Online Database of Chemicals from Around the World

4-氨基-5-氯-N-{1-[3-(4-氟苯氧基)丙基]-3-甲氧基-4-哌啶基}-2-甲氧基苯甲酰胺
[CAS# 104860-73-3]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Abcam 美国 询价快递  
us.orders@abcam.com
化学品生产商(1998 年起)
Achemica 瑞士 询价快递  
+41 (24) 466-2929
contact@achemica.com
化学品生产商(2010 年起)
Achemo Scientific Limited 香港 询价快递  
+852 3174-6428
sales@achemo.com
化学品生产商(2010 年起)
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
ZereneX Molecular Ltd. 英国 询价快递  
+44 (1204) 527-700
sales@zerenex-molecular.com
化学品生产商
基本信息
产品名称 4-氨基-5-氯-N-{1-[3-(4-氟苯氧基)丙基]-3-甲氧基-4-哌啶基}-2-甲氧基苯甲酰胺
英文名 4-Amino-5-Chloro-N-{1-[3-(4-Fluorophenoxy)Propyl]-3-Methoxy-4-Piperidinyl}-2-Methoxybenzamide
别名 (±)-Cisapride
分子结构 CAS 登录号:104860-73-3, 4-氨基-5-氯-N-{1-[3-(4-氟苯氧基)丙基]-3-甲氧基-4-哌啶基}-2-甲氧基苯甲酰胺
分子式 C23H29ClFN3O4
分子量 465.95
CAS 登录号 104860-73-3
分子行输入简码 SMILES COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
国际化学标识码 InChI 1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)
国际化学标识检索码 InChIKey DCSUBABJRXZOMT-UHFFFAOYSA-N
物理化学性质
密度 1.3±0.1g/cm3 (计算值)
沸点 605.4±55.0°C at 760 mmHg (计算值)
闪点 319.9±31.5°C (计算值)
折射率 1.593 (计算值)
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览4-氨基-5-氯-N-{1-[3-(4-氟苯氧基)丙基]-3-甲氧基-4-哌啶基}-2-甲氧基苯甲酰胺市场分析报告总目录
相关产品
N-甲氧基-N-甲基丙酰胺  1-(1,3-二噻烷-2-基)-2,2,2-三氟乙...  4-氨基-2,3,5-三甲基苯酚  2-甲基-4-(2,2,3-三甲基-3-环戊烯-1...  乙基4-(氯磺酰基)苯甲酸酯  1,8-萘啶-3-羧酸  NF 157  8,8'-[羰基二(亚氨基-3,1-亚苯基羰基亚氨...  3,3-二乙氧基-1,2-丙烷二醇  (1S,2R,5S)-2-异丙烯基-5-甲基环己醇  微过氧化物酶 (Mp-11) 钠盐  4-硝基苯基6-O-alpha-D-吡喃半乳糖基-...  6-O-膦酸基-D-甘露糖钡水合物(1:1:2)  3-甲基-3,4-二氢-1H-1,4-苯并二氮杂卓...  铵2-异丙基-5-甲基环己基己o吡喃并s艾杜糖醛酸...